Showing 4 posts of 4 posts found.

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

May 10, 2023
Sales and Marketing Gilead, Oncology, XinThera, inflammation, oncology

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, …


Opioid drugmaker Purdue Pharma inks deal with Alivio over non-opioid inflammation drug

January 29, 2019
Manufacturing and Production Alivio, Purdue Pharma, health, inflammation, opioids

Opioid drugmaker Purdue Pharma has entered into an agreement with inflammatory disease specialist Alivio Therapeutics for the development of the …

Gilead sign

Gilead steps in to rescue Galapagos RA drug

December 18, 2015
Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis

Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …


Amgen joins M&A rush with deals for Dezima and Xencor

September 16, 2015
Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation

Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …

Latest content